Current medications for GCA (eg, glucocorticoids and tocilizumab) target primarily the CD4+ Th17 immune response, possibly leaving residual CD4+ Th1 pathway activity, which may explain why a sizeable proportion of patients flare with these treatments. The gene discussed is CD4; the disease is temporal arteritis.